Pliant reports Q2 2026 results, adds two oncology-focused directors as FORTIFY enrollment continues
PLN-101095 trial enrollment is running ahead of schedule ahead of 2027 interim data, while the company outlines new board additions and cash into second half of 2028.
SEC filing